AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03980834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
Study NCT03342313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food - Sandwich
Description: Sandwich as a breakfast for testing chewing activities.
Study NCT00951301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mangosteen juice
Description: 6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
Study NCT00951301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo juice
Description: 6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
Description: Drug: Locally-used WHO-approved MDR-TB regimen
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofazimine
Description: Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prothionamide
Description: Prothionamide has a bacteriostatic action.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothionamide
Description: Prothionamide has a bacteriostatic action.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kanamycin
Description: Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanamycin
Description: Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
Study NCT02409290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
Study NCT01309139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Medium dose of oral inhalation
Study NCT01309139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: Medium dose of oral inhalation
Study NCT00505596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed free choice
Description: Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
Study NCT03200054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence Clubs
Description: Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last \~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
Study NCT01054950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
Study NCT01054950 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phone call
Description: Phone call w/ no behavioral counseling
Study NCT00515957 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetically modified CTLs in combo with CD45 antibodies
Description: LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level \<100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10\^7 cells/m2~1x 10\^8 cells/m2 3 x 10\^8 cells/m2~1 x 10\^9 cells/m2
Study NCT01431274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: fixed dose combination
Study NCT01431274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: low dose
Study NCT01431274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olodaterol
Description: one dose only
Study NCT01431274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: high dose
Study NCT01431274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study NCT01431274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study NCT01210170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo inhalation before albuterol.
Study NCT01210170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 400 mcg
Description: mometasone inhalation before albuterol.
Study NCT01210170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone 200 mcg
Description: 200ug mometasone before albuterol.
Study NCT01069172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS Laser Surgery
Description: The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
Study NCT01069172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CCC Surgery
Description: Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
Study NCT03241199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: a first-generation tyrosine kinase inhibitors
Study NCT01010633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Loteprednol Etabonate
Description: 1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
Study NCT01010633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: 1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
Study NCT02558387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
Study NCT02463071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585
Description: 1g soft capsule
Study NCT02463071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0585 placebo
Description: 1g soft capsule
Study NCT02463071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD0585 placebo
Description: 1g soft capsule
Study NCT01925898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam - active comparator
Description: Oral midazolam - 0.7mg/kg single dose
Study NCT01925898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Arm: Ketamine
Description: Oral Ketamine 5mg/kg Single dose
Study NCT03086057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPare for Work: Strength Based Case Management (Stage 1)
Description: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
Study NCT03086057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPare for Work: Adherence Training and Counseling (Stage 2)
Description: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
Study NCT03428022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Study NCT03056950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DELFI PTS ii portable tourniquet
Description: A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
Study NCT01195090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: add sitagliptin100mg/d to pre-study OADs
Study NCT01195090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: add pioglitazone 30mg/d to pre-study OADs
Study NCT04387955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biological Sample Collection
Description: * Diagnostic test : biological sample collection at Day 0~* Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~* Anal swabbing at Day 0~* Blood test at Day 0~* Blood test at Month 1~* Blood test at Month 2
Study NCT00888381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (2009 / 2010 formulation)
Description: A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
Study NCT01552655 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Dual-time PET/CT (low-dose)
Description: 4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
Study NCT02238951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health (mHealth)
Description: Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
Study NCT02238951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No mHealth
Description: Participants receive the same evidence-based care coordination without mHealth technology
Study NCT01093625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narafilcon B Contact Lens
Study NCT01093625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: spectacle wearers
Study NCT02427230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.
Study NCT02427230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks.
Study NCT02427230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal electrical stimulator (CefarPeristim Pro)
Description: electrical stimulation
Study NCT02258503 — intervention group
Intervention type: OTHER
Intervention: pain in elderly patients
Study NCT03763669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myoinositol
Description: myo-inositol (2 g. twice a day)
Study NCT03763669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for myoinositol)
Description: (twice a day)
Study NCT01485341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten
Description: gluten is administered once a day at 10g/day for 15 days
Study NCT01485341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rice starch
Description: rice starch is administered once a day at 10 g/day for 15 days
Study NCT02319291 — intervention group
Intervention type: DEVICE
Intervention: P.F.C. Sigma PS150 RP Total Knee System
Description: Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
Study NCT01245387 — intervention group
Intervention type: DRUG
Intervention: Pegaptanib
Description: Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
Study NCT02806154 — intervention group
Intervention type: OTHER
Intervention: DEXA
Description: The appendicular muscle mass measured by DEXA
Study NCT02642016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-0158 (formerly known as KTN-0158)
Description: Single agent CDX-0158 until unacceptable toxicity or progressive disease
Study NCT01523756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test product 1: new ostomy base plate with Coloplast as manufacturer
Description: test product 1 is tested first
Study NCT01523756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test product 2: new ostomy base plate with Coloplast as manufacturer
Description: test product 2 is tested first
Study NCT02616744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronic acid
Description: 150 mg per month oral ibandronate
Study NCT02616744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 oral capsule of placebo per month
Study NCT04233164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol 1mg/kg
Description: Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.
Study NCT04233164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol 250 mg
Description: Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 250 mg of methylprednisolone.
Study NCT01423851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-018
Description: Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
Study NCT01811745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jaques-Dalcroze eurhythmics training
Description: 12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
Study NCT01811745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent exercise training
Description: 12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
Study NCT05300321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frame lens
Description: The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.
Study NCT00570973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic band ligation
Description: Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
Study NCT00570973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS-Implantation
Description: Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,